News

Ophthalmology Times5h
A look at the vorolanib intravitreal insert compared with aflibercept for DME
EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in ...
Ophthalmology Drugs Market to Reach $26.28 Billion by 2030—Vision Care Becomes a Strategic Growth Pillar | MarketsandMarkets™.
What’s powering a $26.28 billion opportunity?The global ophthalmology drugs market, valued at US$18.34 billion in 2024 stood ...
pharmaphorum5h
Boehringer raises hope of oral drug for diabetic eye disease
Boehringer Ingelheim has raised hopes of a more patient-friendly option with the start of phase 2 testing of BI 1815368, ...
PipelineReview.com5d
4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution
EMERYVILLE, CA, USA I July 02, 2025 I 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing ...
The Manila Times6d
Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...